ABBOTT LABORATORIES
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
ABT$110.51+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Shareholders’ Investment
(in millions except shares and per share data)
| Year Ended December 31 | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Common Shares: | |||
| Beginning of Year | |||
| Shares: 2025: 1,991,472,630; 2024: 1,987,883,852; 2023: 1,986,519,278 | $25,153 | $24,869 | $24,709 |
| Issued under incentive stock programs | |||
| Shares: 2025: 5,322,895; 2024: 3,588,778; 2023: 1,364,574 | 295 | 173 | 66 |
| Share-based compensation | 664 | 673 | 646 |
| Issuance of restricted stock awards | (585) | (562) | (552) |
| End of Year | |||
| Shares: 2025: 1,996,795,525; 2024: 1,991,472,630; 2023: 1,987,883,852 | $25,527 | $25,153 | $24,869 |
| Common Shares Held in Treasury: | |||
| Beginning of Year | |||
| Shares: 2025: 259,774,639; 2024: 253,807,494; 2023: 248,724,257 | $(16,844) | $(15,981) | $(15,229) |
| Issued under incentive stock programs | |||
| Shares: 2025: 4,530,646; 2024: 4,423,897; 2023: 4,881,031 | 296 | 280 | 297 |
| Purchased | |||
| Shares: 2025: 4,952,081; 2024: 10,391,042; 2023: 9,964,268 | (629) | (1,143) | (1,049) |
| End of Year | |||
| Shares: 2025: 260,196,074; 2024: 259,774,639; 2023: 253,807,494 | $(17,177) | $(16,844) | $(15,981) |
| Earnings Employed in the Business: | |||
| Beginning of Year | $47,261 | $37,554 | $35,257 |
| Net earnings | 6,524 | 13,402 | 5,723 |
| Cash dividends declared on common shares (per share — 2025: $2.40; 2024: $2.24; 2023: $2.08) | (4,189) | (3,904) | (3,625) |
| Effect of common and treasury share transactions | 185 | 209 | 199 |
| End of Year | $49,781 | $47,261 | $37,554 |
| Accumulated Other Comprehensive Income (Loss): | |||
| Beginning of Year | $(7,906) | $(7,839) | $(8,051) |
| Other comprehensive income (loss) | 1,905 | (67) | 212 |
| End of Year | $(6,001) | $(7,906) | $(7,839) |
| Noncontrolling Interests in Subsidiaries: | |||
| Beginning of Year | $237 | $224 | $219 |
| Changes to noncontrolling ownership interest | 387 | — | — |
| Noncontrolling Interests’ share of income, net of distributions and share repurchases | 17 | 13 | 5 |
| End of Year | $641 | $237 | $224 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.